<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) in tropical Africa represents by far the most <z:e sem="disease" ids="C1333132" disease_type="Neoplastic Process" abbrv="">common tumour</z:e> in children between 0 and 14 years of age, 97% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> being associated with Epstein-Barr virus (EBV) </plain></SENT>
<SENT sid="1" pm="."><plain>In North Africa, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> is about ten times less frequent than in equatorial Africa, but, according to reports from Algeria, 85% of the cases appear to be associated with EBV </plain></SENT>
<SENT sid="2" pm="."><plain>In Western countries, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> represents about 3% of <z:e sem="disease" ids="C1368871" disease_type="Neoplastic Process" abbrv="">childhood tumours</z:e>, 10 to 15% of them EBV-associated </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, from the northern industrialized countries to the equatorial developing countries, increasing incidences of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> type are paralleled by an increasing proportion of EBV-associated cases </plain></SENT>
<SENT sid="4" pm="."><plain>The Ugandan <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> prospective study showed that high antibody titres to <z:mp ids='MP_0001799'>viral</z:mp> capsid antigen (VCA) preceded <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> development by many years, with a quantifiable relationship between the level of VCA antibodies and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> risk </plain></SENT>
<SENT sid="5" pm="."><plain>If an early and/or massive EBV <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infection</z:e> seems to represent the critical event for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> development in equatorial Africa, the favourable conditions for EBV-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> in North Africa and in Europe remain to be investigated </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">Malaria</z:e> appears to favour <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> development through an EBV-specific T-cell <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Chromosomal translocations and oncogene activation, considered as the final step in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development, do not appear to be related to EBV </plain></SENT>
<SENT sid="8" pm="."><plain>Intervention against the virus may represent the ultimate proof of a causal relationship between EBV and the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases around the world </plain></SENT>
</text></document>